Key Highlights
- On April 17, 2026, OpenAI introduced GPT-Rosalind, an artificial intelligence system engineered specifically for pharmaceutical development and biological sciences
- The technology targets the lengthy 10–15 year drug approval process in the United States by enhancing efficiency during preliminary research phases
- Access is provided to approved users through ChatGPT, Codex, and API integration, alongside a complimentary plugin linking to over 50 scientific platforms
- Collaborative partnerships feature Amgen, Moderna, Thermo Fisher Scientific, the Allen Institute, and Novo Nordisk
- Thermo Fisher Scientific demonstrates a GF Score of 86/100, despite company insiders divesting $8.2 million in stock during the last three-month period
On April 17, 2026, OpenAI revealed GPT-Rosalind, an artificial intelligence platform engineered to advance biological sciences, pharmaceutical discovery, and translational medical research.
The platform honors Rosalind Franklin, the pioneering scientist whose contributions were instrumental in uncovering DNA’s molecular architecture.
The pharmaceutical approval process in the United States conventionally spans a decade to fifteen years. OpenAI indicates that GPT-Rosalind was developed to compress the initial phases of this extended timeline.
The system enables researchers to navigate vast volumes of scientific publications, data repositories, and experimental findings with greater efficiency.
It facilitates activities including literature analysis, hypothesis formulation, experiment design, and translating biological sequences into functional predictions.
GPT-Rosalind can be accessed as a research preview via ChatGPT, Codex, and OpenAI’s API platform. Current availability is restricted to vetted enterprise clients within United States borders.
OpenAI simultaneously released a complimentary Life Sciences research plugin for Codex, providing integration with over 50 scientific databases and research instruments.
Performance Metrics and Benchmarks
When evaluated using BixBench, a benchmark measuring practical bioinformatics applications, GPT-Rosalind achieved a score of 0.751, surpassing GPT-5.4’s 0.732 and Grok 4.2’s 0.698.
On the LABBench2 assessment, the platform exceeded GPT-5.4 performance across 6 of 11 research challenges. The most significant improvement appeared in DNA cloning protocol formulation.
OpenAI conducted additional validation with Dyno Therapeutics utilizing proprietary RNA sequences. The model’s predictions placed it above the 95th percentile when compared to human specialist performance.
Strategic Collaborations
OpenAI has established partnerships with Amgen, Moderna, Novo Nordisk, Thermo Fisher Scientific, NVIDIA, Oracle Health and Life Sciences, the Allen Institute, Benchling, and UCSF School of Pharmacy.
According to Amgen’s Senior Vice President of AI and Data, the partnership with OpenAI enables the application of sophisticated technologies in innovative approaches to accelerate therapeutic delivery to patients.
Thermo Fisher Scientific, among the primary collaborators, maintains a market capitalization near $191.76 billion. The corporation specializes in scientific instrumentation, laboratory equipment, and life science reagents.
Thermo Fisher holds a GF Score of 86 out of 100, featuring a Profitability Rank of 8/10 alongside a Growth Rank of 7/10.
During the previous three-month window, Thermo Fisher insiders liquidated $8.2 million in company shares, while no insider purchases were documented during this timeframe.
The platform receives backing from Microsoft, which maintains an established investment partnership with OpenAI.
